Eisai, in alliance with the Global Coalition for Adaptive Research (GCAR) and University of Pittsburgh Medical Center (UPMC), is set to join the REMAP-COVID study designed to assess various treatments for Covid-19.
As part of the study, Eisai’s experimental TLR4 antagonist eritoran will be assessed as a potential treatment for the novel coronavirus infection. The drug candidate is the first immune modulation therapy selected to treat moderate Covid-19 patients in the study.
Go deeper with GlobalData
The study will be conducted at multiple sites across the US, including UPMC health system, with plans to expand to other sites globally.
Eritoran is intended to suppress the over-production and release of multiple pro-inflammatory mediators in order to protect lungs and other organs of Covid-19 patients from damage.
Eisai Neurology business group chief clinical officer Lynn Kramer said: “We are pleased that our investigational immune modulation therapeutic TLR4 antagonist, eritoran, will be studied alone and in combination with other drugs to evaluate the effectiveness in Covid-19 hospitalised patients.
“As part of our human health care mission, we are committed to making a difference for patients, their families, and healthcare professionals across the globe.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataREMAP-COVID is the pandemic model of the REMAP-CAP study designed to explore optimal treatments for severe pneumonia in non-pandemic and pandemic settings.
This is a multi-centre, randomised trial to compare standard of care to multi-active comparators. The primary endpoint of the REMAP-COVID sub-study is organ failure-free days over a 21 day period.
Eisai noted that Eritoran will be assessed in hospitalised patients in the immune modulation arm of the REMAP-COVID study.
REMAP-CAP:COVID study US principal investigator Christopher Seymour said: “By utilising an adaptive design rather than using a traditional trial approach, we are more likely to get to answers faster, while keeping our patients as safe as possible.
“REMAP-COVID is an optimal study to identify potential treatments for Covid-19 as safely, quickly, and effectively as possible.”
To date, REMAP-CAP has recruited more than 1,100 patients at 218 sites across North America, Europe, Australia, and New Zealand.
